Danish drugmaker Novo Nordisk said on Thursday it will invest more than 16 billion crowns ($2.34 billion) to expand its manufacturing capacity at Chartres in France. Europe’s most expensive company by market value, which is struggling to meet growing demand for its obesity drug Wegovy, said the investment would significantly increase capacity for its current and future medicines for serious chronic diseases.